Recent studies revealed that amplification or high expression of PD-L1 was significantly and independently associated with poor survival in HCC patients, which confirmed that the PD-1/PD-L1 axis is a promising potential target for HCC immunotherapy (147). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.